ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walles, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walles, T.
Related Collections
Right arrow Lung - other
Right arrowRelated Article

Ann Thorac Surg 2006;82:2030
© 2006 The Society of Thoracic Surgeons


Original Articles: General Thoracic

Invited commentary

Thorsten Walles, MD

Department of Surgery, Robert-Bosch-Krankenhaus, Auerbachstrasse 110, Stuttgart, 70376 Germany

(Email: twalles{at}yahoo.com).

The concept of isolated lung perfusion to increase the effective chemotherapeutic dose in the target tumor tissue by avoiding systemic side effects has been intensively investigated and has already been clinically applied. Retrograde lung perfusion by cannulating the pulmonary veins is a rather new experimental approach. It is hypothesized that a more homogenous drug distribution in the lung tissue can be attained by retrograde perfusion of the pulmonary artery and the bronchial artery vascular tree. In their article, Krueger and colleagues [1] tested the hypothesis of whether retrograde lung perfusion results in an enhanced drug concentration in pulmonary tumors. They used a rodent model generating pulmonary sarcomatous tumors in the left lower lobe of rats. Their results demonstrate a weak tumor penetration by the applied chemotherapeutic agent (doxorubicin), which was confined to the tumor periphery, whereas higher drug levels were found in the healthy lung tissue. No difference was found between isolated antegrade and retrograde lung perfusion. The authors attribute their findings to a low permeability of the endothelial barrier of the tumor vasculature.

The reason for lower drug concentrations in the generated tumor tissues compared with normal lung parenchyma may be missing vascularization of the growing sarcomatous nodules. The results presented by Krueger and colleagues [1] mirror our experience of capillary ingrowth in a rodent transplant model (ie, avascular tissues with a diameter of less than 1 mm are supplied by diffusion for a time period of 2 weeks) [2]. Tissue revascularization starts approximately 2 weeks after transplantation and continues up to the 8th postoperative week [3]. In their applied animal model, Krueger and coworkers [1] treated the growing sarcomatous tumor already 10 days after seeding. It is suspected that no significant vascularization of the tumor tissue exists at time of treatment. This thesis is supported by the identical effect of antegrade and retrograde lung perfusion and the finding that sporadic fluorescence signaling an emerging from the tumors was confined to the tumor periphery (Fig 2A–D). In contrast, in an acute rodent model applying isolated antegrade and retrograde lung perfusion in healthy lung tissue, recently Romijn and coworkers [4] could show that retrograde lung perfusion increased the drug concentration of melphalan in hilar and basal regions of the lung compared with antegrade perfusion [4]. From this perspective the article of Krueger and coworkers [1] raises numerous interesting questions. Does their applied animal model allow the growth of tumor tissue for a period of 4 weeks and longer? If so, does the tumor tissue become revascularized? Finally, does antegrade or retrograde lung perfusion cause different effects in these vascularized tumors?


    References
 Top
 References
 

  1. Krueger T, Kuemmerle T, Andrejevic-Blant S, et al. Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model Ann Thorac Surg 2006;82:2024-2030.[Abstract/Free Full Text]
  2. Walles T, Herden T, Haverich A, Mertsching H. Influence of scaffold thickness and scaffold composition on bioartificial graft survival Biomaterials 2003;24:1233-1239.[Medline]
  3. Walles T, Puschmann C, Haverich A, Mertsching H. Acellular scaffold implantation—no alternative to tissue engineering Tissue Eng 2003;26(3):225-234.
  4. Romijn S, Hendriks JM, Van Putte BP, et al. Anterograde versus retrograde isolated lung perfusion with melphalan in the WAG-Rij rat Eur J Cardiothorac Surg 2005;27(6):1083-1085.[Abstract/Free Full Text]

Related Article


: .




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walles, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walles, T.
Related Collections
Right arrow Lung - other
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS